Therefore, low doses of unconjugated DD1 or DFc could be suitable to saturate EGFR binding sites of normal tissues 6–24 h before injecting any anti-EGFR MMAE conjugate and push its anti-tumor efficacy. The gene discussed is EGFR; the disease is neoplasm.